Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

NCT04671433 is registered in ClinicalTrials.gov with MeiraGTx Ocular UK Ltd as lead sponsor.

NCT NCT04671433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04671433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Lead sponsor
MeiraGTx Ocular UK Ltd
Phase
Phase 3
Overall status
Completed
Start date
December 4, 2020
Completion date
September 30, 2024
Enrollment
105 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

x-linked retinitis pigmentosa